Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.

Background: Achieving a functional or sterilizing cure for HIV will require identification of therapeutic interventions that reduce HIV reservoir size in infected individuals. Proteasome inhibitors, such as ixazomib, impact multiple aspects of HIV biology including latency, transcription initiation,...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Nathan W Cummins, Jason Baker, Rana Chakraborty, Patrick G Dean, Enrique Garcia-Rivera, Ashton Krogman, Shaji Kumar, Yury V Kuzmichev, Gregory M Laird, Alan Landay, Mathias Lichterfeld, Maryam Mahmood, Jeffrey Martinson, Mark Maynes, Sekar Natesampillai, Vincent Rajkumar, Yelizaveta Rassadkina, Kristen D. Ritter, Christina G Rivera, Stacey A Rizza, Krupa Subramanian, Aaron J Tande, Elizabeth R Wonderlich, Jennifer A Whitaker, John Zeuli, Andrew D Badley
Format:	article
Langue:	EN
Publié:	Elsevier 2021
Sujets:	HIV Latent reservoir Proteasome inhibitor Ixazomib Medicine (General) R5-920
Accès en ligne:	https://doaj.org/article/9bcbc1806c0c4535bde930e29c873a95
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.

Documents similaires